Croissy-Beaubourg, June 3, 2018, 6pm CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and in vitro diagnostics, announces the voting results of its Annual Ordinary and Extraordinary General Meeting, held on…
Result of the votes at Theradiag’s Annual and Extraordinary General MeetingChange in the composition of the Board of Directors chaired by Gérard Tobelem The Board of Directors reaffirms its confidence in the CEOUpdate regarding the HOB…
Consolidated 2017 revenue: €9.1 million Discontinuation of the Prestizia activity and termination of agreements with HOB Biotech, entailing exceptional charges of €3.7 million Net loss of €2.2 million excluding exceptional charges and €0.8 million for 2017 at…